
Estrafleg Gel 0.06% (80 GM)
$57.98 / unit
Available Options
| Pack Size | Price | Price / Unit | Quantity | Action |
|---|---|---|---|---|
| 10 Gel | $434.00 | $43.40/unit | ||
| 8 Gel | $347.00 | $43.38/unit | ||
| 6 Gel | $263.00 | $43.83/unit | ||
| 4 Gel | $184.00 | $46.00/unit | ||
| 2 Gel | $104.00 | $52.00/unit | ||
| 1 Gel | $58.00 | $58.00/unit |
Product Description
ESTRAFLEG GEL 0.06% 80 GM
Brand Name: Estrafleg Gel 0.06% 80 GM
Generic Name: 17-Beta Estradiol
Strength: 0.06% w/w
Dosage Form: Transdermal Gel
Therapeutic Class: Estrogen Hormone / Hormone Replacement Therapy (HRT)
Brand Listed By: Quinek Life Sciences
Manufacturer: Not independently verified; confirm from product packaging
Pack Size: 1 × 80 GM Gel Container
What is this medicine?
ESTRAFLEG GEL 0.06% 80 GM contains 17-Beta Estradiol 0.06% w/w, a form of estrogen hormone used in hormone replacement therapy (HRT).
Estradiol is a naturally occurring estrogen hormone primarily produced by the ovaries. It plays an important role in regulating reproductive functions, maintaining bone health, and supporting various physiological processes.
During menopause, estrogen production decreases, which may cause symptoms such as hot flashes, night sweats, vaginal dryness, and sleep disturbances.
Estrafleg Gel works by delivering estradiol through the skin into the bloodstream. It helps replace declining estrogen levels and may reduce symptoms associated with estrogen deficiency.
This medicine may be prescribed for:
Moderate to severe hot flashes associated with menopause
Night sweats caused by declining estrogen levels
Menopausal symptoms related to estrogen deficiency
Sleep disturbances associated with menopausal hot flashes
Vaginal dryness and discomfort associated with menopause
Hormone replacement therapy in postmenopausal women
Estrogen deficiency due to certain medical conditions, when clinically appropriate
Supporting endometrial preparation in selected fertility treatment protocols under specialist supervision
Prevention of postmenopausal osteoporosis in selected patients when the particular product is approved and alternative treatments are unsuitable
NOTE: Estrafleg Gel 0.06% 80 GM is a systemic estrogen treatment intended for application to the skin. It is not a vaginal gel and should not be applied inside the vagina.
Hormone replacement therapy should be used only after appropriate medical evaluation of its benefits and risks.
Women who have a uterus generally require an appropriate progestogen alongside systemic estrogen to reduce the risk of endometrial cancer, unless a specialist determines otherwise.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
Allergy to estradiol or any ingredient of the gel
Breast cancer or a history of breast cancer
Known or suspected estrogen-dependent cancer
Endometrial cancer
Unexplained vaginal bleeding
History of blood clots in the legs or lungs
Deep vein thrombosis (DVT)
Pulmonary embolism
History of stroke or heart attack
Known blood-clotting disorders
Active liver disease or severe liver impairment
High blood pressure
Diabetes
High cholesterol or triglyceride levels
Migraine headaches
Gallbladder disease
Endometriosis
Uterine fibroids
Systemic lupus erythematosus
Epilepsy
Asthma
Kidney disease
History of fluid retention
Pregnancy or suspected pregnancy
Breastfeeding
Planned major surgery
Prolonged immobilization
Smoking, particularly when combined with other cardiovascular risk factors
Inform your healthcare provider about all prescription medicines, nonprescription medicines, vitamins, supplements, and herbal products you are currently taking.
Important: Systemic estrogen therapy may increase the risk of blood clots, stroke, and certain hormone-sensitive cancers in susceptible patients.
Estrogen therapy should not be started in patients with active or previous thromboembolic disease or known estrogen-dependent cancers unless a specialist establishes an appropriate indication under applicable guidance.
How should I use this medicine?
Use this medicine exactly as prescribed by your healthcare provider.
Wash your hands before applying the gel.
Make sure the application area is clean and completely dry.
Apply the prescribed amount of gel to the approved skin area.
Follow the specific application-site instructions printed on the Estrafleg packaging.
Spread the gel gently over the recommended skin surface.
Allow the gel to dry completely before dressing.
Do not apply the gel to the breasts.
Do not apply the gel inside or around the vagina unless the product is specifically formulated and prescribed for that route.
Avoid applying to broken, irritated, or damaged skin.
Avoid contact with the eyes, mouth, and other mucous membranes.
Wash your hands thoroughly after application.
Do not wash the treated area for the period specified in the product instructions.
Avoid allowing another person, particularly a child, to touch the treated skin before it has dried and is appropriately covered.
Apply the gel at approximately the same time each day.
Do not increase the amount applied without medical advice.
Follow your healthcare provider's instructions regarding additional progesterone or progestogen treatment.
Attend regular medical follow-up appointments to evaluate treatment response.
Usual Application Frequency: Estradiol 0.06% transdermal gel is commonly applied once daily. The exact amount depends on the formulation, dispensing device, indication, and prescribed treatment regimen.
Dose Measurement: The gel contains 0.6 mg of estradiol per gram. Some other 0.06% estradiol pump products deliver 1.25 g of gel containing 0.75 mg estradiol per actuation. This delivery amount has not been verified for Estrafleg and must not be assumed to apply to its container.
Starting Dose: The dose should be determined by the treating physician and measured using the manufacturer's specified method.
Duration of Treatment: Depends on the underlying indication, symptom severity, individual risk factors, and clinical response. Treatment should be reviewed periodically to determine whether it remains necessary.
Expected Results: Improvement in menopausal hot flashes may occur within the first few weeks of treatment. Full symptom control may take longer and varies between individuals.
Overdosage: Excessive estrogen exposure may cause nausea, vomiting, breast tenderness, abdominal discomfort, bloating, headache, or vaginal bleeding. Seek medical advice if excessive amounts are used.
NOTE: Estrafleg Gel 0.06% 80 GM should only be used as directed by a qualified healthcare professional. The amount of gel prescribed must be based on the exact product's instructions and individual treatment requirements.
What if I miss a dose?
Apply the missed dose when you remember, provided it is not nearly time for your next scheduled dose.
If it is almost time for the next dose, skip the missed application.
Continue with your normal treatment schedule.
Do not apply a double quantity to compensate for a missed dose.
Avoid applying additional gel without medical advice.
Contact your healthcare provider if you miss several consecutive applications.
Follow any product-specific missed-dose instructions provided with the medicine.
Important: Missing doses may allow menopausal symptoms to return. Consistent application helps maintain more stable estrogen exposure.
What may interact with this medicine?
Estradiol may interact with medicines that affect hormone metabolism, blood clotting, or the effectiveness of hormone therapy.
Potential interactions include:
Rifampicin
Rifabutin
Carbamazepine
Phenytoin
Phenobarbital
Primidone
St John's wort
Certain antiretroviral medicines
Certain antifungal medicines
Certain antibiotics that affect hormone metabolism
Lamotrigine
Thyroid hormone replacement medicines
Warfarin and other anticoagulants
Certain enzyme-inducing anticonvulsants
Other estrogen-containing medicines
Certain hormonal therapies
Important Drug Interaction Considerations
Enzyme-Inducing Medicines: Rifampicin, carbamazepine, phenytoin, and phenobarbital may increase estrogen metabolism and reduce estradiol exposure.
St John's Wort: This herbal supplement may reduce the effectiveness of estrogen treatment by increasing hormone metabolism.
Antifungal Medicines: Certain antifungal medicines may alter estrogen metabolism and increase systemic hormone exposure.
Lamotrigine: Estrogen therapy may reduce lamotrigine concentrations in some patients, potentially affecting seizure control. Dose monitoring may be necessary.
Thyroid Hormones: Estrogen therapy can affect thyroid hormone-binding proteins and may alter thyroid hormone requirements, particularly in patients taking levothyroxine.
Anticoagulants: Estrogen therapy may influence clotting risk. Patients taking anticoagulants require individual medical assessment and monitoring.
Other Hormonal Medicines: Combining estrogen with other hormone treatments should only be done under professional supervision.
Important: Drug interactions depend on the specific medicine, dose, and individual medical history. Inform your healthcare provider about all medicines you take before starting estradiol therapy.
What should I watch for while using this medicine?
Seek immediate medical attention if you experience:
Sudden chest pain
Difficulty breathing
Coughing up blood
Sudden severe headache
Sudden vision loss or visual disturbances
Weakness or numbness on one side of the body
Difficulty speaking
Painful swelling or redness in one leg
Severe allergic reactions
Swelling of the face, lips, tongue, or throat
Severe or persistent unexplained vaginal bleeding
Severe abdominal pain
Yellowing of the skin or eyes
While using this medicine:
Attend regular follow-up appointments.
Monitor whether menopausal symptoms improve.
Report unusual vaginal bleeding or spotting.
Follow recommended breast screening schedules.
Report new breast lumps or unusual breast changes.
Monitor blood pressure when clinically appropriate.
Inform your doctor about severe or persistent headaches.
Report significant swelling or fluid retention.
Follow recommendations for cardiovascular risk assessment.
Maintain a healthy body weight.
Avoid smoking.
Follow a balanced diet and regular exercise routine.
Discuss bone health with your healthcare provider.
Inform your doctor before major surgery or prolonged immobilization.
Avoid unnecessary long-term estrogen therapy.
Follow prescribed progestogen treatment if you have a uterus.
Do not use estrogen therapy solely to prevent cardiovascular disease or dementia.
NOTE: Women with an intact uterus who use systemic estrogen without adequate endometrial protection may have an increased risk of endometrial hyperplasia and cancer.
Your healthcare provider may prescribe a progestogen to reduce this risk.
Hormone therapy should be reviewed periodically to assess continued benefits and potential risks.
What side effects may I notice from this medicine?
Side effects that should be reported immediately:
Blood clots in the legs or lungs
Stroke-like symptoms
Chest pain or symptoms of a heart attack
Severe allergic reactions
Sudden vision changes
Severe or persistent unexplained vaginal bleeding
Severe headache with neurological symptoms
Signs of serious liver problems
Severe abdominal pain
Significant leg swelling or pain
Serious skin reactions
New breast lumps requiring evaluation
Side effects that usually do not require medical attention:
Breast tenderness
Breast discomfort
Headache
Mild nausea
Abdominal bloating
Mild fluid retention
Mild swelling of the hands or feet
Skin redness at the application site
Mild itching
Skin irritation
Mild rash
Changes in vaginal discharge
Vaginal spotting
Changes in menstrual bleeding patterns
Mild dizziness
These side effects may be more noticeable when treatment begins or the dose is adjusted.
Some symptoms may improve as the body adjusts to hormone treatment.
Contact your healthcare provider if they persist, become troublesome, or worsen.
Important: Unexplained vaginal bleeding during systemic estrogen therapy should be evaluated by a healthcare professional.
Although transdermal estrogen may have a different clotting-risk profile from oral estrogen, serious cardiovascular and thromboembolic risks must still be considered.
Where should I keep my medicine?
Keep out of the reach of children.
Store according to the temperature instructions printed on the original packaging.
Available supplier information for Estrafleg recommends storage below 30°C.
Protect from excessive heat.
Protect from direct sunlight.
Keep the container tightly closed.
Store in a cool, dry place.
Do not freeze the gel.
Keep away from flames, sparks, and other ignition sources if the formulation contains alcohol.
Do not smoke while applying the gel.
Allow the gel to dry completely before exposure to potential ignition sources.
Keep the medicine in its original container.
Do not use after the expiry date.
Do not use if the container is damaged.
Avoid transferring the gel into unlabelled containers.
Dispose of expired or unused medicine according to your pharmacist's instructions.
Storage Note: Estrafleg supplier listings recommend storage below 30°C. The exact storage and flammability precautions should be confirmed against the original product label.
Manufacturer Details
Field | Information |
|---|---|
Brand Name | Estrafleg Gel 0.06% 80 GM |
Generic Name | 17-Beta Estradiol |
Strength | 0.06% w/w (0.6 mg/g) |
Dosage Form | Transdermal Gel |
Therapeutic Class | Estrogen Hormone / Hormone Replacement Therapy |
Indication | Management of Menopausal Symptoms and Estrogen Deficiency |
Brand Listed By | Quinek Life Sciences |
Manufacturer | Not independently verified; confirm original packaging |
Prescription Status | Prescription Hormonal Medicine |
Storage | Store Below 30°C According to Supplier Listing; Follow Original Label |
Route of Administration | Transdermal / External Application |
Pack Size | 1 × 80 GM Container |
Packaging Type | Pump Bottle |
Country of Origin | India |






